Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)

SHE:300026 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	5,686	5,757	6,025	6,603	7,656	6,463
Other Revenue	26.24	26.24	84.31	47.44	14.63	25.37
Revenue	5,712	5,783	6,109	6,650	7,671	6,488
Revenue Growth (YoY)	-3.40%	-5.34%	-8.14%	-13.30%	18.22%	29.69%
Cost of Revenue	2,750	2,793	2,827	2,826	3,267	2,858
Gross Profit	2,962	2,989	3,282	3,824	4,403	3,630
Selling, General & Admin	2,521	2,534	2,463	2,751	3,054	2,648
Research & Development	226.57	223.45	209.81	230.85	196.59	177.03
Other Operating Expenses	54.45	48.74	41.4	61.72	76.44	1.87
Operating Expenses	2,869	2,887	2,767	3,100	3,401	2,896
Operating Income	92.54	102.42	515.52	724.42	1,002	733.98
Interest Expense	-34.64	-44.86	-61.57	-69.67	-50.1	-30.07
Interest & Investment Income	13.65	17.31	19.31	14.18	11.38	12.03
Currency Exchange Gain (Loss)	3.92	3.92	2.41	17.62	-6.34	-29.34
Other Non Operating Income (Expenses)	-23.3	-22.2	-18.49	-35.65	-26.86	21.11
EBT Excluding Unusual Items	52.17	56.59	457.19	650.91	930.58	707.71
Impairment of Goodwill	-17.34	-17.34	-23.52	-	-58.18	-
Gain (Loss) on Sale of Investments	-5.54	-5.63	-1.4	-	-22.98	-
Gain (Loss) on Sale of Assets	1	1.08	1.06	0.01	-2.87	0.03
Asset Writedown	-31.77	-30.33	-4.05	-2.36	-9.35	-24.3
Other Unusual Items	55.4	49.62	177.54	67.82	16.99	-0.03
Pretax Income	53.93	53.98	606.82	716.37	854.18	683.41
Income Tax Expense	23.49	31.04	105.25	95.14	183.32	123.73
Earnings From Continuing Operations	30.43	22.95	501.57	621.23	670.85	559.68
Minority Interest in Earnings	-6.76	-1.48	5.06	3.01	16.47	13.71
Net Income	23.68	21.47	506.63	624.24	687.32	573.39
Net Income to Common	23.68	21.47	506.63	624.24	687.32	573.39
Net Income Growth	-93.92%	-95.76%	-18.84%	-9.18%	19.87%	42.45%
Shares Outstanding (Basic)	2,174	2,147	2,980	2,973	2,988	3,018
Shares Outstanding (Diluted)	2,174	2,147	2,980	2,973	2,988	3,018
Shares Change (YoY)	-26.93%	-27.97%	0.26%	-0.53%	-0.98%	4.96%
EPS (Basic)	0.01	0.01	0.17	0.21	0.23	0.19
EPS (Diluted)	0.01	0.01	0.17	0.21	0.23	0.19
EPS Growth	-91.68%	-94.12%	-19.05%	-8.70%	21.05%	35.71%
Free Cash Flow	629.57	659.12	1,183	-24.93	-285.85	-367.12
Free Cash Flow Per Share	0.29	0.31	0.40	-0.01	-0.10	-0.12
Dividend Per Share	0.030	0.030	0.030	0.030	0.040	0.040
Dividend Growth	-	-	-	-25.00%	-	-20.00%
Gross Margin	51.85%	51.69%	53.73%	57.50%	57.40%	55.95%
Operating Margin	1.62%	1.77%	8.44%	10.89%	13.07%	11.31%
Profit Margin	0.41%	0.37%	8.29%	9.39%	8.96%	8.84%
Free Cash Flow Margin	11.02%	11.40%	19.36%	-0.38%	-3.73%	-5.66%
EBITDA	375.42	387.15	807.69	974.09	1,217	923.97
EBITDA Margin	6.57%	6.69%	13.22%	14.65%	15.86%	14.24%
D&A For EBITDA	282.88	284.74	292.17	249.67	214.2	189.99
EBIT	92.54	102.42	515.52	724.42	1,002	733.98
EBIT Margin	1.62%	1.77%	8.44%	10.89%	13.07%	11.31%
Effective Tax Rate	43.57%	57.49%	17.34%	13.28%	21.46%	18.11%
Revenue as Reported	5,712	5,783	6,109	6,650	7,671	6,488
Advertising Expenses	-	8.6	9.15	12.6	21.21	19.45

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.